Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 5/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16221756 | 0.94 | CASP2 (0.70) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL10036114 | 0.92 | CASP2 (0.74) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL23080582 | 0.92 | CASP2 (0.74) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL2318684 | 0.91 | CASP2 (0.71) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL10607338 | 0.89 | FAAH (0.61) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL20380836 | 0.88 | FAAH (0.65) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL19477804 | 0.88 | FAAH (0.65) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL9921404 | 0.86 | CASP2 (0.48) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL21012625 | 0.86 | CASP2 (0.55) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL18627446 | 0.86 | CASP2 (0.71) | CASP2NAAAFAAHDNM1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293562-A1 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | SAPREME TECHNOLOGIES B.V. (NL) | 2023-09-21 | — | — | US | disclosed |
| US-20230218783-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME | CARDINAL HEALTH 414, LLC | 2023-07-13 | — | — | US | disclosed |
| US-20220211680-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME | CARDINAL HEALTH 414, LLC | 2022-07-07 | — | — | US | disclosed |
| US-11369680-B2 | Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210338827-A1 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND TREATMENT OF VIRAL INFECTIONS | SCOTT, JOHN KIM, JR. | 2021-11-04 | — | — | US | disclosed |
| US-20210275698-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME | CARDINAL HEALTH 414, LLC | 2021-09-09 | — | — | US | disclosed |
| US-11007272-B1 | Compounds and methods for diagnosis and treatment of viral infections | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10806803-B2 | Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis | OHIO STATE INNOVATION FOUNDATION (US) | 2020-10-20 | — | — | US | disclosed |
| US-20180099048-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING LEISHMANIASIS AND METHODS OF DIAGNOSIS AND TREATING USING SAME | SCOTT, JOHN KIM, JR. | 2018-04-12 | — | — | US | disclosed |
| WO-2018068060-A1 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND TREATMENT OF VIRAL INFECTIONS | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20140194480-A1 | METHODS FOR THE CONTROL OF TERMITES AND ANTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-07-10 | — | — | US | disclosed |
| US-20130210623-A1 | PESTICIDAL MIXTURES INCLUDING ISOXAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130203591-A1 | PESTICIDAL MIXTURES INCLUDING ISOXAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130184450-A1 | METHOD FOR PREPARING RIBONUCLEOSIDE PHOSPHOROTHIOATE | THE UNIVERSITY OF TOKYO (JP) | 2013-07-18 | — | — | US | disclosed |
| US-8173764-B2 | Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers | ALLEXCEL INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8147854-B2 | Cosmetics comprising a modified organopolysiloxane | DOW CORNING TORAY COMPANY, LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8013094-B2 | Gelling agents and gelatinous compositions | DOW CORNING TORAY COMPANY, LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100260743-A1 | Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers | ALLEXCEL, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100028391-A1 | Cosmetics Comprising A Modified Organopolysiloxane | DOW CORNING TORAY COMPANY, LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029862-A1 | Gelling Agents And Gelatinous Compositions | DOW CORNING TORAY COMPANY, LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099048-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING LEISHMANIASIS AND METHODS OF DIAGNOSIS AND TREATING USING SAME | MPO, SGMS2, SGMS1 | CASP2 549/4885NAAA 370/4885FAAH 2051/4885 |
| US-20230293562-A1 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | ASGR1, HCCS, HAVCR2 | CASP2 2644/4885NAAA 3815/4885FAAH 3275/4885 |
| US-10806803-B2 | Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis | CD209, CD68, MSR1 | CASP2 2245/4885NAAA 1718/4885FAAH 1408/4885 |
| US-11007272-B1 | Compounds and methods for diagnosis and treatment of viral infections | HAVCR2, DDX5, DDOST | CASP2 1353/4885NAAA 391/4885FAAH 1916/4885 |
| US-20100028391-A1 | Cosmetics Comprising A Modified Organopolysiloxane | H1-0, H1-2, CHRM1 | CASP2 4144/4885NAAA 3749/4885FAAH 3698/4885 |
| US-20220211680-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME | MSR1, CD14, CLEC4M | CASP2 2286/4885NAAA 2074/4885FAAH 2451/4885 |
| US-20210338827-A1 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND TREATMENT OF VIRAL INFECTIONS | HAVCR2, DDX5, DDOST | CASP2 1353/4885NAAA 391/4885FAAH 1916/4885 |
| US-20230218783-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME | MSR1, CD14, CLEC4M | CASP2 2286/4885NAAA 2074/4885FAAH 2451/4885 |
| US-20140194480-A1 | METHODS FOR THE CONTROL OF TERMITES AND ANTS | CYP2S1, CYP2F1, HRH4 | CASP2 2663/4885NAAA 2606/4885FAAH 855/4885 |
| US-11369680-B2 | Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same | MPO, SGMS2, SGMS1 | CASP2 549/4885NAAA 370/4885FAAH 2051/4885 |
| US-20130210623-A1 | PESTICIDAL MIXTURES INCLUDING ISOXAZOLINE DERIVATIVES | CHRM1, ACHE, CYP4X1 | CASP2 920/4885NAAA 950/4885FAAH 2527/4885 |
| US-20130184450-A1 | METHOD FOR PREPARING RIBONUCLEOSIDE PHOSPHOROTHIOATE | RNGTT, RNMT, TRDMT1 | CASP2 3454/4885NAAA 3161/4885FAAH 4870/4885 |
| US-20130203591-A1 | PESTICIDAL MIXTURES INCLUDING ISOXAZOLINE DERIVATIVES | CYP4X1, CHRM1, ACHE | CASP2 800/4885NAAA 1027/4885FAAH 2607/4885 |
| US-20100260743-A1 | Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers | CD44, ABCG2, ABCC1 | CASP2 1377/4885NAAA 1484/4885FAAH 1368/4885 |
| US-20210275698-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME | MSR1, CD14, CLEC4M | CASP2 2286/4885NAAA 2074/4885FAAH 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.